Article
Tumor–stromal metabolic crosstalk in pancreatic cancer
26 May 2025
Abstract excerpt
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a dire prognosis. Standard-of-care chemotherapy regimens offer marginal survival benefit and carry risk of severe toxicity, while immunotherapy approaches have uniformly failed in clinical trials. Extensive desmoplasia in the PDAC tumor microenvironment (TME) disrupts blood flow to and from the tumor, thereby creating a nutrient-depleted,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
